Clinical trials: Complication of Dialysis
Hyperphosphatemia, Chronic Kidney Disease, Receiving Dialysis
A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China
The goal of this clinical trial is to learn if AP301 could work in the patients receiving maintenance dialysis with elevated blood phosphate.
- Conditions
- Hyperphosphatemia, Chronic Kidney Disease, Receiving Dialysis, ESRD (End-Stage Renal Disease), Dialysis
- Trial name
- RESPOND-2 (NCT06933472)
- Testing
- AP301, AP301 Low Dose
- Where
- 42 sites in United States, China
- Volunteers
- 264 people
- Sponsor
- Alebund Pharmaceuticals
Hyperphosphatemia, Chronic Kidney Disease
Placebo Versus SBR759 in Lowering Phosphate in Dialysis Patients
This study will compare placebo to 4 different doses of SBR759 to assess the phosphate lowering efficacy in dialysis patients.
- Trial name
- SBR759 (NCT01069692)
- Testing
- SBR759A
- Where
- 9 sites in Belgium, Italy
- Volunteers
- 115 people
- Sponsor
- Novartis
End-stage Renal Disease
The Feasibility and Safety of an Intradialytic Exercise Program: DIALY-SIZE
The primary aim of this pilot study is to evaluate the feasibility and safety of four different types of intradialytic exercise (exercise performed during dialysis) programs: resistance, aerobic, combined resistance and aerobic…
- Trial name
- NCT02234232
- Testing
- Exercise
- Where
- Canada
- Volunteers
- 31 people
- Sponsor
- University of Alberta
Quality of Life
Monitoring the Quality of Life of Patients With End-stage Renal Disease (QV-REIN)
The main purpose for holding this survey is epidemiological surveillance, it must provide the indicators that contribute to the evaluation of the plan "improvement of the quality of life in chronic diseases" and monitoring the…
- Trial name
- NCT02890264
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Central Hospital, Nancy, France
ESRD (End Stage Renal Disease), Chronic Kidney Disease(CKD)
AP301 Efficacy and Safety in Chinese Dialysis Patients With Hyperphosphatemia
This Phase 3 clinical trial is the pivotal study of AP301 aiming to evaluate the efficacy and safety of AP301 for controlling serum phosphorus in chronic kidney disease receiving hemodialysis and peritoneal dialysis in Chinese…
- Conditions
- ESRD (End Stage Renal Disease), Chronic Kidney Disease(CKD), Hyperphosphatemia, Hyperphosphatemia in Chronic Kidney Disease
- Trial name
- RESPOND-1 (NCT07030595)
- Testing
- AP301, Sevelamer carbonate (Renvela®), AP301 Low Dose
- Where
- 50 sites in China
- Volunteers
- 474 people
- Sponsor
- Alebund Pharmaceuticals
End Stage Renal Disease
Impact on Quality of Life of Symptoms Routine E-monitoring Among Dialysis Patients.
In France, end-stage renal disease (ESRD) affects almost 170 people per million inhabitants every year, and 92,500 people are treated by dialysis or kidney transplantation (0.14% of the French population).
- Trial name
- F-SWIFT (NCT06257134)
- Testing
- No systematic monitoring of symptoms, Systematic monitoring of symptoms
- Where
- 3 sites in France
- Volunteers
- 2,293 people, healthy volunteers welcome
- Sponsor
- Central Hospital, Nancy, France
Mechanical Complication of Peritoneal Dialysis Catheter
Prophylactic Omentopexy During Laparoscopic Insertion of Peritoneal Dialysis Catheter
The purpose of this study is to compare function of the peritoneal dialysis catheter in two groups of patients with and without prophylactic omentopexy that was performed during laparoscopic insertion of peritoneal catheters.
- Trial name
- NCT02879734
- Testing
- Prophylactic laparoscopic omentopexy
- Where
- Iran
- Volunteers
- 40 people
- Sponsor
- Tehran University of Medical Sciences
End Stage Renal Disease
Choice Sets for Advance Directives
There is a large gap between the care seriously ill patients want and the care they receive. Advance directives (ADs) offer an opportunity for patients to express specific end-of-life preferences to avoid unwanted care.
- Trial name
- NCT02209038
- Testing
- Expanded AD Choice, Expanded Life-sustaining Therapy Choice
- Where
- 15 sites in United States
- Volunteers
- 321 people
- Sponsor
- University of Pennsylvania
End Stage Renal Disease, Peritoneal Dialysis Complication
The Effect of Home Based Tele-Exercise on Peritoneal Dialysis Patients
Brief Summary: The objective of the trial is to assess the effect of synchronous home-based tele exercise on daily activity level, functional status and frailty level in Peritoneal Dialysis patients.
- Trial name
- NCT06787599
- Testing
- Home-based Tele Exercise
- Where
- Iran
- Volunteers
- 30 people
- Sponsor
- Pardis Specialized Wellness Institute
Anemia, Renal Insufficiency, Chronic
Long Term Extension Study for the Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934
Evaluate efficacy and safety up to 36 months of titrated dose treatment with BAY85-3934 versus epoetin alfa/beta. Titration will be based on the subject's hemoglobin (Hb) response and tolerability of the prior dose.
- Trial name
- DIALOGUE5 (NCT02064426)
- Testing
- Molidustat (BAY85-3934), Epoetin alfa/beta
- Where
- 26 sites in United States, Japan
- Volunteers
- 88 people
- Sponsor
- Bayer
Renal Failure
Restenosis Following Paclitaxel Eluting Balloon Angioplasty of Hemodialysis Access Stenosis
Introduction: Narrowing of the draining vein occurs in >50% of hemodialysis fistula and left untreated will lead to loss of access. The narrowing is due to excessive growth of tissue in the vessel wall (intimal hyperplasia).
- Trial name
- NCT01001676
- Testing
- Percutaneous Transluminal Angioplasty (PTA), Paclitaxel Eluting Balloon Angioplasty
- Where
- Canada
- Volunteers
- 32 people
- Sponsor
- University Health Network, Toronto
End Stage Renal Disease
Evaluating Aranesp® in Subjects With End Stage Renal Disease onChronic Hemodialysis
The purpose of this study is to assess the Aranesp® dose administered intravenously (IV) once weekly to maintain hemoglobin (Hgb) levels in hemodialysis subjects who are either recombinant human erythropoietin (rHuEPO) naïve or…
- Trial name
- NCT00117104
- Testing
- Aranesp®
- Sponsor
- Amgen
Chronic Kidney Disease
Molecule Removal and Ease of Use: A Comparison of Two Different Dialyzers
The Polyflux HD-C4 (Gambro Renal Products) is a new dialyzer based on the existing Polyflux H membrane and dialyzer technology, but which achieves a performance comparable to Polyflux 210H in a significantly smaller device.
- Trial name
- NCT00636389
- Testing
- Polyflux 210H dialyzer, Polyflux HD-C4
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Vantive Health LLC
Chronic Kidney Disease Stage 5 (Dialysis Dependent)
A Randomized, Comparative, Open-label Study of IV Monofer® Administered as Maintenance Therapy by Single or Repeated Bolus Injections in Comparison With IV Iron Sucrose in Subjects With CKD-5D
The purpose of this study is to compare the efficacy and safety of intravenous iron isomaltoside 1000 with intravenous iron sucrose in patients suffering from Stage 5 Chronic Kidney Disease on Dialysis Therapy (CKD-5D).
- Trial name
- NCT01222884
- Testing
- Monofer, Iron sucrose
- Where
- India
- Volunteers
- 351 people
- Sponsor
- Pharmacosmos A/S
Chronic Kidney Diseases, Chronic Kidney Disease stage3
Validation and Evaluation of a Newly Developed Mobile Diet App
A 12-week, prospective, multicenter, open-label pilot randomized controlled trial (RCT) will be carried out to determine the feasibility, acceptability and potential clinical efficacy of a newly developed mobile diet app among…
- Conditions
- Chronic Kidney Diseases, Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Chronic Kidney Disease Stage 5
- Trial name
- NCT04336033
- Testing
- Counseling, Renal Diet App, Printed Nutrition Pamphlet
- Where
- Malaysia
- Volunteers
- 90 people
- Sponsor
- Universiti Putra Malaysia
Uremia
Elimination of Incretin Hormones in Patients With Severe Kidney Failure
The prevalence of type 2 diabetes (T2D) is increasing rapidly worldwide. T2D is characterized by a severely impaired incretin effect.
- Trial name
- NCT01391884
- Where
- Denmark
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Bo Feldt-Rasmussen
Anemia
Treatment of Anemia in Diabetic Subjects With CKD
The purpose of this study is to compare the proportion of subjects receiving either Epoetin alfa (PROCRIT®) or placebo who are able to achieve a hemoglobin response, defined by at least a 1 gram/deciliter increase from baseline…
- Trial name
- NCT00240734
- Testing
- Epoetin alfa
- Volunteers
- 11 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Renal Disease
A Pharmacokinetic Study of Sugammadex in Dialysis Patients
The primary objective of this prospective study is to assess the trend of sugammadex (and its complex with rocuronium) concentration in surgical patients with routine outpatient hemodialysis.
- Trial name
- NCT04556721
- Testing
- Sugammadex
- Where
- United States
- Sponsor
- Tetsuro Sakai
End Stage Renal Disease on Dialysis
Assessment of D-dimer and CRP for Cardiovascular Risk Prediction in Hemodialysis Patients
This study aims to assess whether two blood markers - C-reactive protein (CRP) and D-dimer - can help predict cardiovascular complications in patients undergoing regular hemodialysis.
- Trial name
- BIOCARD-HD (NCT07130721)
- Testing
- C-Reactive Protein (CRP) Test, D-dimer Test, Electrocardiogram (ECG)
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Assiut University
PAD - Peripheral Arterial Disease, AAA - Abdominal Aortic Aneurysm
Retrospective Post-Market Clinical Follow-Up Study of GORE-TEX® Vascular Grafts and GORE® PROPATEN® Vascular Graft in Peripheral Artery Disease, Aortic Aneurysms, and Dialysis Access
This multicenter, single-arm retrospective registry (chart review) is being conducted to confirm the clinical performance and safety of GORE-TEX® Vascular Grafts and GORE® PROPATEN® Vascular Graft throughout the device functional…
- Conditions
- PAD - Peripheral Arterial Disease, AAA - Abdominal Aortic Aneurysm, End-Stage Renal Disease
- Trial name
- NCT05124184
- Testing
- GORE® PROPATEN® Vascular Graft, GORE-TEX® Vascular Grafts
- Where
- 8 sites in France, Italy and 1 more
- Volunteers
- 356 people
- Sponsor
- W.L.Gore & Associates
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.